Aurora Cannabis Teams Up With UFC to Study CBD Use for Pain Management in MMA Athletes

August 7, 2019 08:00:16

Aurora Cannabis, a cannabis company based in Edmonton, is teaming up with the Ultimate Fighting Championship (UFC) to conduct research into how CBD can be used for pain management among mixed martial arts (MMA) athletes.

This partnership is expected to result in several studies that will investigate the role of CBD in managing inflammation, pain, wound healing as well as recovery from intense training.

The research is intended to understand the specific health and recovery needs of the elite athletes who take part in the highly competitive mixed martial arts. The information gathered during the studies will be the basis upon which specially formulated products will be developed for use by MMA athletes to deal with the different health-related challenges that they face.

The Ultimate Fighting Championship revealed that under WADA and USADA regulations, cannabidiol (CBD) is allowed. However, the UFC intends to go a step further and take part in this research so that it can lead the way in educating MMA athletes about the best way in which they can use CBD.

The actual clinical study will be carried out in Las Vegas at the UFC Performance Institute. Dr. Jason Dyck, who heads the Global Scientific Oversight Committee of Aurora Cannabis, will lead the team conducting the research. The research team will also have performance experts taken from the UFC Performance Institute.

Speaking at the unveiling of the partnership, Terry Booth (Aurora Cannabis CEO) said that the company is using this research and the science-based products that they will develop as an entry point to get into the U.S. CBD market.

Kyle Murray, the vice dean at the Alberta School of Business (Alberta University) remarked that he was initially surprised to hear about this partnership, but soon realized that mixed martial arts athletes make a good population to study since their sport is so competitive and physically demanding.

The UFC will ask athletes to enroll for this study voluntarily so that the scientists can establish whether CBD can enhance performance or lower it, whether the compound is good for the athletes or not, what modes of administration give the best outcomes, if any, and any drawbacks to using CBD products, especially topicals.

Such collaborations are a direct result of the legalization of industrial hemp and its derivatives in the U.S. when the 2018 Farm Bill was signed into law by President Donald Trump in December last year.

Industry pundits think CBD industry players like Green Growth Brands Inc. (CSE: GGB) (OTCQB: GGBXF) and Hemptown USA will be pleased that such research partnerships are being formed. The products made after such research will help to make the industry more reputable, and that is good for everyone involved.

About CBDWire

CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published:

Do you have a questions or are you interested in working with CNW? Ask Our Editor

Denver, Colorado
303.498.7722 Office